Home > Insider Trading > Filing (0001012975-18-001198)

Filing Details

Accession Number:: 0001012975-18-001198
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-11-06 16:31:12
Reporting Period:: 2018-11-02

Accepted Time:: 2018-11-06 16:31:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1581280	Twist Bioscience Corp	TWST	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219042	Robert Nelsen	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1219043	Clinton Bybee	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1402439	Arch Venture Fund Vii, L.p.	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1544443	Arch Venture Partners Vii, Llc	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1544444	Arch Venture Partners Vii, L.p.	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1616165	Arch Venture Partners Viii, Llc	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1617237	Arch Venture Fund Viii Overage, L.p.	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-11-02	1,182,645	$0.00	1,182,645	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-11-02	718,275	$0.00	1,900,920	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-11-02	266,776	$0.00	2,167,696	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-11-02	224,726	$0.00	2,392,422	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-11-02	15,000	$14.00	2,407,422	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2018-11-02	894,146	$0.00	894,146	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-11-02	60,000	$14.00	954,146	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2018-11-02	1,182,645	$0.00	1,182,645	$0.00
Common Stock	Series B Preferred Stock	Disposition	2018-11-02	718,275	$0.00	718,275	$0.00
Common Stock	Series C Preferred Stock	Disposition	2018-11-02	266,776	$0.00	266,776	$0.00
Common Stock	Series D Preferred Stock	Disposition	2018-11-02	224,726	$0.00	224,726	$0.00
Common Stock	Series D Preferred Stock	Disposition	2018-11-02	894,146	$0.00	894,146	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.
The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Reflects shares purchased in the Issuer's initial public offering.
The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The expiration date is not relevant to the conversion of these securities.